 |
PDBsum entry 4g8o
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Blood clotting/inhibitor
|
PDB id
|
|
|
|
4g8o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Blood clotting/inhibitor
|
 |
|
Title:
|
 |
Crystal structure of a novel small molecule inactivator bound to plasminogen activator inhibitor-1
|
|
Structure:
|
 |
Plasminogen activator inhibitor 1. Chain: a, b, c, d. Fragment: unp residues 28-402. Synonym: pai, pai-1, endothelial plasminogen activator inhibitor, serpin e1. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: pai-1, pai1, planh1, serpine1. Expressed in: escherichia coli. Expression_system_taxid: 469008.
|
|
Resolution:
|
 |
|
2.71Å
|
R-factor:
|
0.241
|
R-free:
|
0.268
|
|
|
Authors:
|
 |
J.A.Stuckey,D.A.Lawrence,S.-H.Li
|
|
Key ref:
|
 |
S.H.Li
et al.
(2013).
Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.
Proc Natl Acad Sci U S A,
110,
E4941.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
23-Jul-12
|
Release date:
|
25-Dec-13
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P05121
(PAI1_HUMAN) -
Plasminogen activator inhibitor 1 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
402 a.a.
359 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 5 residue positions (black
crosses)
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
110:E4941
(2013)
|
|
PubMed id:
|
|
|
|
|
| |
|
Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.
|
|
S.H.Li,
A.A.Reinke,
K.L.Sanders,
C.D.Emal,
J.C.Whisstock,
J.A.Stuckey,
D.A.Lawrence.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Plasminogen activator inhibitor type-1 (PAI-1) is a member of the serine
protease inhibitor (serpin) family. Excessive PAI-1 activity is associated with
human disease, making it an attractive pharmaceutical target. However, like
other serpins, PAI-1 has a labile structure, making it a difficult target for
the development of small molecule inhibitors, and to date, there are no US Food
and Drug Administration-approved small molecule inactivators of any serpins.
Here we describe the mechanistic and structural characterization of a high
affinity inactivator of PAI-1. This molecule binds to PAI-1 reversibly and acts
through an allosteric mechanism that inhibits PAI-1 binding to proteases and to
its cofactor vitronectin. The binding site is identified by X-ray
crystallography and mutagenesis as a pocket at the interface of β-sheets B and
C and α-helix H. A similar pocket is present on other serpins, suggesting that
this site could be a common target in this structurally conserved protein family.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |